Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model.

We developed an abiraterone population pharmacokinetic model and proposed an advanced approach to medical adherence evaluation. Due to the need for administration under fasting conditions, abiraterone therapy is associated with a relatively high rate of non-adherence.